Cytomegalovirus News and Research

RSS

Cytomegalovirus (CMV) is a member of the herpes virus group, which includes herpes simplex virus types 1 and 2, varicella-zoster virus (which causes chickenpox), and Epstein-Barr virus (which causes infectious mononucleosis). Infection with CMV is a major cause of disease and death in immunocompromised patients, including organ transplant recipients, patients undergoing hemodialysis, patients with cancer, patients receiving immunosuppressive drugs, and HIV-infected patients. While drugs are available for treatment of these conditions, the primary drug choices carry significant side effects and warnings. Currently, there are no anti-CMV drugs indicated for treatment of primary CMV infection during pregnancy resulting in infections that can have catastrophic consequences to the newborn. Maternal-fetal transfer of CMV infection results in a fetal death rate of 12% and most survivors have permanent debilitating disorders, including mental retardation, vision loss, and sensorineural deafness.

Innovative approach for creating a cytomegalovirus vaccine

Each year, about 40,000 children are born infected with human cytomegalovirus, or CMV, and about 8,000 of these children suffer permanent disabilities due to the virus - almost one an hour.

2 Aug 2006

Epstein-Barr virus may trigger multiple sclerosis

Researchers have found that patients with multiple sclerosis (MS) carry a population of immune cells that overreact to Epstein-Barr virus.

3 May 2006

FDA grants fast track status for ViroPharma's Maribavir

ViroPharma Incorporated has announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for maribavir, an oral antiviral drug candidate for the prevention of cytomegalovirus (CMV) infection in allogeneic bone marrow (stem cell) and solid organ transplant patients.

7 Feb 2006

Cellular mechanism discovery could lead to new treatments for rheumatoid arthritis, multiple sclerosis and Crohn's disease

A major finding by researchers at the La Jolla Institute for Allergy & Immunology (LIAI) has identified a previously unknown cellular mechanism that acts as an off switch for immune system function.

12 Sep 2005

FDA grants Vical orphan-drug designation

Vical Incorporated today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has designated the company's bivalent (two-plasmid) formulation of the company's vaccine against cytomegalovirus (CMV) as an orphan drug for the prevention of clinically significant CMV viremia, CMV disease and associated complications in at-risk hematopoietic cell transplant (HCT) and solid organ transplant (SOT) populations.

14 Jun 2005

Association between chronic cytomegalovirus (CMV) and frailty syndrome

Older women with chronic cytomegalovirus (CMV), a lifelong viral infection, were found to have more than triple the risk of being frail than those who did not have the infection, as reported in the Journal of the American Geriatrics Society. This is the first demonstration to show an association between CMV and frailty syndrome.

9 Jun 2005

Research provides roadmap for the development of human therapies for cytomegalovirus (CMV)

McGill University Health Centre (MUHC) researchers have defined genetic resistance to the widespread virus, cytomegalovirus (CMV)--a member of the viral group that causes some of the world's most prevalent diseases, such as herpes, chicken pox and mononucleosis.

26 May 2005

Tarvacin shows significant anti-viral activity

Peregrine Pharmaceuticals today announced that there will be two presentations, April 4 and 6, at the American Association of Immunologists (AAI) annual meeting in San Diego, California, indicating the anti-viral potential of its Tarvacin antibody. Dr. Melina Soares of The University of Texas Southwestern Medical Center at Dallas will present pre-clinical data titled "Targeting inside-out phospholipids on viruses in a guinea pig model of Lassa fever."

4 Apr 2005

Potential cure for lymphoma in HIV patients

Stem cell transplants have become the standard of care for patients with relapsed lymphoma, but not for patients who suffer from both this disease and HIV.

7 Jan 2005

The burgeoning Indian AIDS epidemic

India, home to one-sixth of the human race, has an AIDS epidemic. Five million Indians are living with HIV infection. The stakes are high; the government is racing against time.

21 Dec 2004

Scientists discover a record number of proteins for the highly infectious and stealthy human cytomegalovirus

Scientists have discovered a record number of proteins for one of the largest and most complex viruses, the highly infectious and stealthy human cytomegalovirus, a team from Pacific Northwest National Laboratory and Oregon Health & Science University reported today in the October Journal of Virology.

29 Sep 2004

Long-term outcomes for liver transplantation due to hepatitis C

A new study on liver transplants necessitated by the hepatitis C virus (the most common indication for this type of transplant) found that long-term outcomes are similar to patients receiving transplants due to other diseases.

8 Sep 2004

Drug to fight virus from the herpes family in transplant patients moves forward in trials

A drug once considered for cancer chemotherapy is advancing in clinical trials to test its effectiveness in fighting a virus from the herpes family that threatens transplant patients.

29 Jul 2004

Autism antibodies are not genetically determined, as parents do not exhibit them

Autism produces a widespread range of antibodies that act against brain tissue and one protein in particular seems to be the major target of these antibodies claim a group of scientists in the July issue of the Journal of Neuroimmunology.

23 Jul 2004

Discovery may explain why people with AIDS may suffer severe infections from viruses that they would otherwise defeat

Researchers have uncovered the first evidence that a virus can mutate to evade the body's first line of immune defense.

25 Jun 2004

Treatment of cytomegalovirus remains a priority in order to improve the prognosis for people with HIV-1 infection

Treatment of cytomegalovirus infection remains a priority in order to improve the prognosis for people with HIV-1 infection, including people already receiving antiretroviral therapy

24 Jun 2004

New findings may help better understand how harmless viruses can cause severe disease among patients with weakened immune systems

When a major branch of the mouse immune system is disabled, a normally harmless virus can rapidly mutate into a lethal one, according to researchers at Washington University School of Medicine in St. Louis.

17 Jun 2004

Women exposed in adulthood to cytomegalovirus may be at greater risk of breast cancer

A study just published in the prestigious British Journal of Cancer by researchers at the University of Otago's Christchurch School of Medicine and Health Sciences and Dunedin School of Medicine, and the University of Melbourne, has found evidence of a link between a common virus and breast cancer in women under the age of 40 years.

31 May 2004

$3.5 million grant to develop AIDS vaccinations

Researchers at the Vaccine and Gene Therapy Institute (VGTI) and the Oregon National Primate Research Center at Oregon Health & Science University have received a $3.5 million grant from the National Institutes of Health to develop new methods for vaccinating humans against human immunodeficiency virus (HIV), the virus that causes AIDS.

25 May 2004

Intranasal influenza vaccine may help induce broader immunity in children than the traditional flu shot

MedImmune, Inc. has announced clinical data showing that a live, attenuated intranasal influenza vaccine (LAIV) may help induce broader immunity in children against drifted influenza strains when compared to the traditional flu shot (TIV).

2 May 2004